WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
A royally starCourtois set to play 1st game of season for Real Madrid after recovering from injuriesAntetokounmpo sits, Lillard returns as Bucks face Pacers in Game 6 of playoff seriesKenya president postpones reopening of schools as floodTen jet lag busters! Airline crew's tips to make longSoccer fan arrested in Marseille as authorities investigate reports of Nazi salute, monkey chantsSouthern Brazil has been hit by the worst floods in 80 years. At least 37 people have diedBaby Reindeer creator Richard Gadd reveals why he has banned his parents from watching Netflix hitJustice Department warns it plans to sue Iowa over new state immigration lawRussian activist gets 15
2.9013s , 6491.125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Connection news portal